The useful way to follow the retina industry is not to count press releases. It is to track milestones that change evidence, regulatory status, clinical capability or the economics of care—and to distinguish those milestones from promotional announcements.
- Regulatory decisions, pivotal-trial readouts and clinically meaningful platform changes carry more weight than ordinary product marketing.
- In 2026, retinal AI, home monitoring, gene therapy, biosimilars and integrated imaging workflows are moving simultaneously.
- This page is designed to be updated with source-backed status changes rather than replaced by disposable news posts.
How this tracker works
Retina is an unusually active intersection of devices, drugs, software and advanced therapeutics. That creates a lot of news and a lot of noise. Industry Watch uses a simple filter: did something materially change? We prioritize FDA decisions, trial-stage transitions, pivotal results, meaningful clearances, new evidence about deployment, and changes that alter how retina care can be delivered or paid for. We do not treat every conference booth, partnership or corporate presentation as a milestone. Each item should be traceable to the type of source behind it so readers can distinguish a regulatory record from a manufacturer statement or a clinical publication.
Regulatory: retinal diagnostic AI remains active
FDA's retinal diagnostic software category continues to evolve. The July 2026 510(k) decision for iPredict-DR adds another system to a market that traces its regulatory structure back to the 2018 De Novo authorization of IDx-DR. Multiple entries make the category easier to analyze as a market: buyers can compare intended use, acquisition requirements, workflow, evidence and deployment models rather than treating autonomous retinal AI as a singular novelty.
Remote monitoring: home OCT tests a different care model
Home OCT represents a shift from clinic-centered imaging toward remote longitudinal monitoring. The most important developments will not be incremental hardware announcements but evidence that remote scanning changes treatment timing, visit burden or outcomes. Manufacturer materials define the intended role as monitoring between clinical encounters rather than replacing comprehensive examinations. What matters next is whether prospective evidence and reimbursement support a scalable care pathway around that capability.
Clinical development: gene therapy reaches broader questions
Retinal gene therapy has moved beyond proving that one approved therapy can work for one genetic target. The current challenge is whether broader strategies can succeed in heterogeneous inherited retinal disease. OCU400's Phase 3 study is worth following because the modifier-gene approach aims at a wider retinitis-pigmentosa population than a single-mutation therapy. The milestone that matters is evidence from the pivotal program on function, safety and durability, followed by any regulatory submission or decision—not another presentation slide.
Therapeutics: biosimilar competition reaches retina
Aflibercept biosimilars introduce a new economic dynamic into anti-VEGF treatment. FDA's approval of interchangeable biosimilars to Eylea created the regulatory foundation, while the commercial story will be determined by contracts, payer policy, supply and practice adoption. At the same time, branded therapies are competing on durability and treatment burden. These approaches solve different problems, so Industry Watch will track both rather than collapse them into a single price comparison.
Platforms: imaging companies are selling workflows
Retina imaging is becoming increasingly platform-oriented. Companies such as ZEISS are presenting integrated diagnostic and surgical workflows that combine OCT, widefield imaging, digital review and AI-guided analysis. The milestone to watch is not whether integration exists in a demonstration; it is whether users can show that it reduces friction, improves longitudinal comparison or produces better decisions. Interoperability will be especially important as practices accumulate data across multiple vendors.
What does not make the list
We deliberately exclude ordinary corporate activity unless it changes the state of evidence or care. A partnership without a deployed product, a preclinical result without human data, a conference abstract that does not materially change prior evidence, or a promotional claim without a traceable source may still be interesting, but it does not automatically belong here. This rule is designed to keep Industry Watch from becoming a press-release feed.
What we are watching next
The next updates should come from five directions: new FDA decisions in retinal AI or imaging; prospective evidence for home monitoring; Phase 3 gene-therapy data and regulatory milestones; real-world adoption of aflibercept biosimilars; and evidence around integrated AI imaging workflows. When an item changes, this page should be updated with the date, source and why the change matters rather than simply adding another headline.
This is a living industry tracker, not investment advice or a product recommendation. Status statements should be rechecked against the linked primary source whenever the article is updated.
Sources & original records
We prioritize primary records, clinical-trial registries, peer-reviewed literature and authoritative institutions. Manufacturer material is labeled when used to describe a product or company position.
- FDA De Novo: IDx-DRU.S. Food and Drug Administration · Regulatory record
- 510(k) Premarket Notification: iPredict-DR (K253704)U.S. Food and Drug Administration · Regulatory record
- Clinical trial NCT06388200: OCU400 Phase 3 studyClinicalTrials.gov · Clinical trial registry
- FDA approves first interchangeable biosimilars to EyleaU.S. Food and Drug Administration · Regulatory announcement
- ZEISS at EURETINA 2026ZEISS Medical Technology · Manufacturer information